Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study
- 1Fujian Maternity and Child Health Hospital
Abstract
Objective Catheter-related thrombosis (CRT) poses significant risks for gynecologic cancer patients with central venous access devices. This retrospective cohort study evaluated the association between prophylactic rivaroxaban and catheter-related thrombosis in gynecologic oncology outpatients. Methods This single-center study at Fujian Maternity and Child Health Hospital (January 2021–June 2025) included 351 gynecologic oncology patients with peripherally inserted central catheters or implantable venous access ports. Primary exposure was rivaroxaban 10 mg daily for ≥ 30 days. Primary outcome was imaging-confirmed catheter-related thrombosis within 180 days. Inverse probability of treatment weighting (IPTW) was used to address confounding. Results Among 351 patients (120 rivaroxaban, 231 controls), CRT occurred in 3 (2.5%) versus 42 (18.2%) patients, respectively (hazard ratio [HR] 0.12, 95% confidence interval [CI] 0.04–0.41; p < 0.001). The IPTW analysis confirmed this association (weighted HR 0.14, 95% CI 0.05–0.44). Major bleeding rates were 1.7% vs. 0.4% (HR 3.86, 95% CI 0.35–42.75; p = 0.273). Clinically relevant non-major bleeding occurred in 6.7% vs. 3.0% (HR 2.23, 95% CI 0.81–6.16; p = 0.121). Conclusion In this retrospective cohort study, prophylactic rivaroxaban was associated with lower catheter-related thrombosis incidence in gynecologic cancer patients. These observational findings warrant prospective randomized validation. Clinical trial number Not applicable.
Related
- De-escalated rivaroxaban in postoperative isolated distal deep vein thrombosis: a propensity score–matched study
- Anticoagulant Prophylaxis with Edoxaban for Asymptomatic Isolated Distal Deep Vein Thrombosis in Perioperative Hip Fracture Patients.
- Empirical Antibiotic Initiation for Suspected Early-Onset Neonatal Infection in the Setting of Maternal GBS Screening and Intrapartum Antibiotic Prophylaxis: A Single-Center Retrospective Cohort Study
- Single-dose versus short-course antibiotic prophylaxis in laparoscopic right hemicolectomy with intracorporeal anastomosis: a retrospective cohort study
- Lipedema-Related Outcomes During Gestrinone Treatment for Estrogen-Dependent Gynecological Disorders: A Real-World Retrospective Case Series.
BibTeX
@article{xie2026rivaroxaban,
title = {{Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study}},
author = {Qing Xie and Tianhong Cai and Beier Huang},
journal = {Thrombosis Journal},
year = {2026},
month = jul,
doi = {10.1186/s12959-026-00904-2},
url = {https://doi.org/10.1186/s12959-026-00904-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study
AU - Qing Xie
AU - Tianhong Cai
AU - Beier Huang
PY - 2026
DA - 2026/07/01
JO - Thrombosis Journal
DO - 10.1186/s12959-026-00904-2
UR - https://doi.org/10.1186/s12959-026-00904-2
AB - Objective Catheter-related thrombosis (CRT) poses significant risks for gynecologic cancer patients with central venous access devices. This retrospective cohort study evaluated the association between prophylactic rivaroxaban and catheter-related thrombosis in gynecologic oncology outpatients. Methods This single-center study at Fujian Maternity and Child Health Hospital (January 2021–June 2025) included 351 gynecologic oncology patients with peripherally inserted central catheters or implantable venous access ports. Primary exposure was rivaroxaban 10 mg daily for ≥ 30 days. Primary outcome was imaging-confirmed catheter-related thrombosis within 180 days. Inverse probability of treatment weighting (IPTW) was used to address confounding. Results Among 351 patients (120 rivaroxaban, 231 controls), CRT occurred in 3 (2.5%) versus 42 (18.2%) patients, respectively (hazard ratio [HR] 0.12, 95% confidence interval [CI] 0.04–0.41; p < 0.001). The IPTW analysis confirmed this association (weighted HR 0.14, 95% CI 0.05–0.44). Major bleeding rates were 1.7% vs. 0.4% (HR 3.86, 95% CI 0.35–42.75; p = 0.273). Clinically relevant non-major bleeding occurred in 6.7% vs. 3.0% (HR 2.23, 95% CI 0.81–6.16; p = 0.121). Conclusion In this retrospective cohort study, prophylactic rivaroxaban was associated with lower catheter-related thrombosis incidence in gynecologic cancer patients. These observational findings warrant prospective randomized validation. Clinical trial number Not applicable.
SN - 1477-9560
ER -